Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron

The recurrent emerging of novel viral variants of concern (VOCs) with evasion of preexisting antibody immunity upholds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) case numbers and maintains a persistent demand for updated therapies. We selected the patient-derived antibody CV38-142...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreye, Jakob, Reincke, S. Momsen, Edelburg, Stefan, Jeworowski, Lara M., Kornau, Hans-Christian, Trimpert, Jakob, Hombach, Peter, Halbe, Sophia, Nölle, Volker, Meyer, Martin, Kattenbach, Stefanie, Sánchez-Sendin, Elisa, Schmidt, Marie L., Schwarz, Tatjana, Rose, Ruben, Krumbholz, Andi, Merz, Sophie, Adler, Julia M., Eschke, Kathrin, Abdelgawad, Azza, Schmitz, Dietmar, Sander, Leif E., Janssen, Uwe, Corman, Victor M., Prüss, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979625/
https://www.ncbi.nlm.nih.gov/pubmed/36925720
http://dx.doi.org/10.1016/j.isci.2023.106323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979625/
https://www.ncbi.nlm.nih.gov/pubmed/36925720
http://dx.doi.org/10.1016/j.isci.2023.106323

Ejemplares similares